Clinical trial / 2018
A Khorasan wheat replacement diet reduced liver enzymes and inflammatory markers in NAFLD.
Forty adults with mild to moderate nonalcoholic fatty liver disease were randomized to consume ancient KAMUT khorasan or modern wheat products for 3 months. Compared with baseline, the khorasan group had significant reductions in alanine aminotransferase by 12%, aspartate aminotransferase by 14%, alkaline phosphatase by 8%, and cholesterol by 6% (all p < 0.05). Proinflammatory cytokines decreased significantly only with khorasan, while steatosis grading and reactive oxygen species improved in both study groups.
- Study type
- Randomized controlled trial
- Who was studied
- 40 adults with nonalcoholic fatty liver disease
- What was measured
- Liver enzymes, inflammatory markers, and liver steatosis
THE PAPER
A Khorasan Wheat-Based Replacement Diet Improves Risk Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD): A Randomized Clinical Trial.
Dinu M, Whittaker A, Pagliai G, Giangrandi I, Colombini B, Gori AM, Fiorillo C, Becatti M, Casini A, Benedettelli S, Sofi F. J Am Coll Nutr, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.